Juvenile Idiopathic Arthritis Clinical Trial
Official title:
The Effect of Whole Body Vibration Therapy on Muscle Function and Joint Loading in Children With Juvenile Idiopathic Arthritis
Juvenile idiopathic arthritis (JIA) is one of the most common chronic illnesses in children, with recent data suggesting that 1 to 4 in 1000 Canadian children and youth cope with the condition. Many JIA children will enter adulthood with permanent joint damage5. In parallel, a significant number are affected by deficits of muscle function. In addition to the impact on physical function, muscles play an important role in maintaining joint health. The overall aim of this proposal is to evaluate a novel therapeutic intervention - whole body vibration (WBV) - for its ability to improve muscle function and the biomechanics of lower extremity joints in JIA in order to prevent joint degeneration.
This project aims to evaluate the effect of a therapy called whole body vibration (WBV) on
muscle function and joint biomechanics in children and adolescents suffering from juvenile
idiopathic arthritis (JIA).
JIA is the most common chronic form of arthritis in children and affects at least 1 in 1000
Canadian children and youth. Current data suggests that a large number of children suffering
from JIA will encounter permanent joint damage, to which direct effects of inflammation are
an important contributor. Nevertheless, recent research has also shown that impaired muscle
function and a subsequent alteration of joint loading might by itself induce joint damage.
Fifty percent of JIA patients have significant impairments of muscle function and this is
often present in patients who do not have active arthritis anymore. In addition to optimum
medical treatment of the disease, it is therefore important to improve muscle function in
order to protect the joints.
WBV therapy might be an interesting technique to achieve this in JIA patients. It is able to
improve muscle function very efficiently with relatively short training times and at the same
time confers loads to the lower limbs which are only 30% of body weight. The WBV device
consists of a plate going up and down along a fulcrum at a high frequency. The patient stands
on the WBV device and the vibration will induce muscle stretch reflexes producing muscle
contractions. These muscle contractions are similar to muscle activity during exercise and
are not perceived as painful or unpleasant. The technique has been used in children with
several conditions impairing muscle function.
The primary question to be investigated in the proposed study is whether WBV therapy will
significantly improve muscle function in JIA patients. In addition, the effect of an
improvement in muscle function on gait and the loading of individual joints at the lower
extremity will be examined. Finally the effect of WBV therapy on quality of life will be
assessed.
We propose conducting a controlled trial investigation. This implies, that one group of study
participants, called the intervention group, will do the WBV therapy, whereas a second group,
called the control group, will just follow their daily habitual activities. All participants
will have an initial assessment of muscle function, electrical muscle activity and joint
biomechanics by completely painless measurement techniques at the Children's Hospital of
Eastern Ontario (CHEO) and a nearby Human Motion Biomechanics lab at the University of
Ottawa. In addition, an MRI of the lower legs without contrast media will be done to confirm
the absence of joint effusions as well as bone or muscle edema. Quality of life will be
assessed by a standard questionnaire that has been validated in JIA. Subsequently, study
participants in the intervention group as well as their parents will be introduced to the
therapy during two separate sessions at the CHEO. They will then take a WBV device home and
perform 6 minutes of training on 5 days a week for 3 months. Each month, they will return to
CHEO for assessment of muscle function and demonstration of training technique. At the end of
the 3 month period, both intervention and control group patients will repeat the initial set
of assessments including MRI. After another 3 month period, all participants will return for
a final assessment of muscle function and joint biomechanics but not MRI to document
persistence of any change observed.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02776735 -
An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)
|
Phase 2 | |
Active, not recruiting |
NCT03092427 -
Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA)
|
N/A | |
Not yet recruiting |
NCT05545098 -
MSUS Versus Serum Survivin and Lubricin Levels in Evaluation of Disease Activity in JIA
|
||
Not yet recruiting |
NCT03833609 -
Yoga and Aerobic Dance for Pain Management in Juvenile Idiopathic Arthritis
|
N/A | |
Completed |
NCT02524340 -
Patient Centered Adaptive Treatment Strategies Using Bayesian Causal Inference
|
||
Recruiting |
NCT01434082 -
Sleep Patterns in Children With and Without Juvenile Idiopathic Arthritis
|
N/A | |
Completed |
NCT04671524 -
The Effect of Improvement in Function on Foot Pressure, Balance and Gait in Children With Upper Extremity Affected
|
N/A | |
Recruiting |
NCT04167488 -
Assessment of Physical Activity Among Juvenile Idiopathic Arthritis Children Performed With Actigraphy
|
N/A | |
Recruiting |
NCT04205500 -
Treatment With Specific Carbohydrate Diet in Children With Juvenile Idiopathic Arthritis
|
N/A | |
Terminated |
NCT01694264 -
Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα
|
Phase 3 | |
Completed |
NCT02824978 -
Therapeutic Alliance is it Associated With Better Compliance Amongst Children With Juvenile Idiopathic Arthritis ?
|
||
Active, not recruiting |
NCT03841357 -
Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
|
Phase 3 | |
Completed |
NCT03833271 -
The Efficacy of Influenza Vaccine Program in Children With Juvenile Idiopathic Arthritis. A Single Centre Results From Hungary
|
Early Phase 1 | |
Completed |
NCT01455701 -
A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)
|
Phase 1 | |
Completed |
NCT05031104 -
Low-energy Laser Applications in Patients With Juvenile Idiopathic Arthritis
|
N/A | |
Not yet recruiting |
NCT01436019 -
Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis
|
N/A | |
Recruiting |
NCT05609630 -
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
|
Phase 3 | |
Recruiting |
NCT05696340 -
Access to Pediatric Rheumatology Centers for JIA Patients: Factors Associated With Time to Access Pediatric Rheumatology Centers
|
||
Recruiting |
NCT05545839 -
Transition to Adulthood Through Coaching and Empowerment in Rheumatology
|
N/A | |
Completed |
NCT05436301 -
Turkish Validity and Reliability of Pain Catastrophizing Scale-Child (PCS-C)
|